SCHD's Stunning Reversal: Schwab's Flagship Dividend ETF Is Up 29% and Climbing

Schwab U.S. Dividend Equity ETF (SCHD) has returned 29.29% year-to-date, roughly 18 percentage points ahead of the S&P 500's approximately 11% gain. The fund has benefited from investor rotation away from expensive AI and megacap technology stocks toward lower-volatility dividend payers amid geopolitical uncertainty and tariffs. SCHD's limited exposure to struggling megacap tech and its March 2026 index refresh, which added UnitedHealth, Procter & Gamble, and Accenture, also supported performance.

Analysis

The relevant signal is factor-flow persistence rather than a durable re-rating of every dividend payer. A 29% YTD move leaves SCHD vulnerable to crowded "quality/value" positioning: if long-duration growth stabilizes, the ETF can underperform quickly despite unchanged constituent fundamentals. The next 1-3 month determinant is whether real yields decline without a material growth scare; that backdrop supports dividend multiples, while a rebound in the 10-year real yield would compress the defensives now carrying the quality bid.

SCHD is not a pure defensive exposure. QCOM and TXN retain meaningful handset, industrial and auto-cycle sensitivity; COP and CVX introduce direct oil-price beta; HD remains exposed to housing turnover and renovation demand. This creates a useful second-order setup: a benign soft landing can support the fund, but an actual recession would likely expose dispersion between staples/healthcare (PG, ABT) and cyclicals (HD, QCOM, TXN, COP), limiting the protection investors appear to be pricing into the aggregate vehicle.

The March rebalance should not be treated as proof of incremental alpha: index additions often attract temporary mechanical flows, while their future contribution depends on earnings revisions. UNH is the clearest idiosyncratic risk within the new quality basket, where reimbursement, utilization, or regulatory developments can dominate dividend-factor support. Contrarian view: the rotation is probably under-owned relative to mega-cap growth, but the ETF-level move is sufficiently extended that the better risk-adjusted expression is selective ownership or a factor pair rather than chasing SCHD outright.

Key Decisions for Investors

• Do not initiate a full SCHD long after the breakout; use a 5-8% pullback or a renewed decline in 10-year real yields as entry triggers. A close below the 50-day moving average combined with rising real yields would invalidate the near-term momentum thesis.
• Express the rotation with a 1-3 month pair: long SCHD and short IWF in equal dollar amounts, sized modestly. The trade benefits if earnings dispersion and valuation discipline persist; exit if NVDA/mega-cap earnings revisions turn positive enough to re-accelerate growth leadership.
• For a cleaner defensive sleeve, prefer PG and ABT over HD, QCOM and TXN for the next 6-12 months. The former pair has lower sensitivity to housing and semiconductor inventory normalization; reassess if consumer-staples volume trends weaken or healthcare reimbursement pressure intensifies.
• Treat COP/CVX exposure as a separate oil call rather than a dividend-quality allocation. Reduce or hedge energy beta if Brent breaks below its 200-day moving average or if global-demand estimates are revised down; lower crude would remove a key cash-return support for the group.
• Monitor UNH before adding broad SCHD exposure: a negative medical-cost trend, Medicare reimbursement action, or material guidance cut could create an idiosyncratic drag that factor inflows will not offset.